— Impressive actions with barzolvolimab in cold urticaria, symptomatic dermographism
by Mike Bassett, Personnel Writer, MedPage Today
October 29, 2024
BOSTON– Treatment with an investigational anti-KIT monoclonal antibody caused medically significant reactions in the 2 most typical kinds of persistent inducible urticaria, a dose-ranging stage II trial revealed.
In clients with improperly managed illness regardless of antihistamines, as much as 53% of those with cold urticaria and approximately 58% of those with symptomatic dermographism accomplished a total action (CR) after 12 weeks of treatment with barzolvolimab, rates considerably greater than with placebo (approximately 13%), Jonathan Bernstein, MD, of the University of Cincinnati Medical Center, reported here.
“This is the very first randomized placebo-controlled research study to show medical advantage in clients with persistent inducible urticaria,” he stated at the American College of Allergy, Asthma & & Immunology yearly conference, keeping in mind that there are presently no authorized treatments for the condition beyond antihistamines.
Persistent inducible urticaria is a mast cell-driven illness identified by the advancement of wheals and itch, Bernstein discussed. The condition is set off by cold temperature levels when it comes to cold urticaria and by pressure on the skin in symptomatic dermographism. Signs can last for as long as 6 weeks and can take a considerable physical and mental toll on clients, he stated.
Barzolvolimab prevents the activation of KIT by stem cell elements, which manage the survival and activity of mast cells. The drug has actually likewise shown effectiveness in persistent spontaneous urticaria, where stage III trials are underway.
The existing stage II research study was a double-blind randomized trial including 96 clients with cold urticaria and 97 clients with symptomatic dermographism. Qualified clients had their dia